A1 This century-long endeavor demonstrates a persistent and brave innovative spirit. Today, China has well-established itself as the world's economic stabilizer, and its ambition to forge "a global community of health for all" has deeply impressed the rest of the world.

As a global leader in human vaccines that firmly endorses China's innovation-driven strategy, a similar pioneering spirit has also been embedded into Sanofi Pasteur's corporate DNA.

A2 While listening to President Xi's speech, we could deeply feel China's determination to encourage innovation, advance opening-up and maintain an efficient business environment.

Sanofi Pasteur, for the past 25 years, has been strongly advocating China's reform and opening-up policy and is optimistic about the momentum and potential of the Chinese market.

Standing at a fresh starting point with the new round of higher-level reform and opening-up and embracing emerging opportunities, Sanofi Pasteur is expanding its investment and business presence in China.

It is to launch China's first internationalized innovation center for vaccines in the Guangdong-Hong Kong-Macao Greater Bay Area in the coming months.

A3 In Sanofi Pasteur's view, the grand visions described in China's 14th Five-Year Plan (2021-25) and the long-range objectives throughout 2035 are seen as very attractive, especially the emphasis of strategically prioritizing people's healthcare, forging a "Healthy China "through preventive solutions.

The master plan is ushering in new growth drivers for the Chinese economy, and we are truly inspired to see these blueprints strongly align with our own vision. Rooted in China, Sanofi Pasteur is committed to "Healthy China 2030" and will continue to develop novel preventive solutions, accelerate the launch of innovative high-quality vaccines, work with partners to contribute to public health and support the good health of the Chinese people.

A4 Among other significant trends, the Chinese government's adherence to improving the business environment and its innovation-driven strategy is the point that impresses us the most. Amid unremitting exploration of the industry's future development, Sanofi Pasteur expects to strengthen our collaboration with governments at different levels, striving to effectively play our role as China's most trusted partner in disease prevention.

And in addition to our unwavering efforts in exploring a new model through which to accelerate the introduction of world-leading vaccines to China, we are also committed to better facilitating international cooperation in the R&D of innovative vaccines, improving their accessibility together with government partners and tangibly benefiting the Chinese people through the synchronized application of quality vaccines across the globe.

A5 Sanofi Pasteur is more than thrilled to see China's 14th Five-Year Plan and long-range objectives throughout 2035 strategically prioritize people's healthcare and urge the realization of a "Healthy China" through preventive solutions. From infants to teenagers, adults to seniors, the quality of vaccines matters to every individual that receives them. For the Chinese vaccine industry, which is quickly reaching advanced global standards, further improvement of quality and innovation in products is still much needed.